Benzinga | Jul 16, 2021 08:23AM EDT

Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $224

Morgan Stanley analyst David Lebovitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $205 to $224.